Patent · US Active

High affinity Siglec ligands

US8357671B2 · kind B2 · utility

13Cited by
4References
52Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 10, 2006
Grant dateJan 22, 2013
Priority date
Expiry dateMar 3, 2029

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P35/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to high affinity Siglec ligands that are useful for isolating cells that express Siglecs and for delivering agents to cells that express Siglecs. In one embodiment, the invention provides a method for treating cancer in a mammal that involves administering a Siglec ligand of the invention to the mammal, where the Siglec ligand is linked to a therapeutic agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.